Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysis
The findings suggests that T + D + CT may not be a cost-effectiveness first-line treatment for EGFR/ALK wild-type mNSCLC in the US, given its high ICERs and limited cost-effectiveness in the majority of PD-L1 expression subgroups.
Authors
- Xiaohui Zeng
- Ziying Zhao
- Qiao Liu (ORCID: https://orcid.org/0000-0002-9781-3360)
- Zhen Zhou (ORCID: https://orcid.org/0009-0004-9870-2509)
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Monash University (AU)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.21037/tlcr-24-244
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28